Epigallocatechin-3-O-gallate decreases tumor necrosis factor-α- induced fractalkine expression in endothelial cells by suppressing NF-κB

Cellular Physiology and Biochemistry

Volumn 24, Issue 5-6, 2009, Pages 503-510

  Lee, Ae Sin ^a   Jung, Yu Jin ^a   Kim, Duk Hoon ^a   Lee, Tae Hwan ^a   Kang, Kyung Pyo ^a   Lee, Sik ^a   Lee, Nae Ho ^a   Sung, Mi Jeong ^b   Kwon, Dae Young ^b   Park, Sung Kwang ^a   Kim, Won ^a  

^a Chonbuk National University Medical School   (South Korea)

^b Korea Food Research Institute   (South Korea)

Author keywords

Endothelial cells; Epigallocatechin 3 O gallate; Fractalkine

Indexed keywords

EPIGALLOCATECHIN GALLATE; FRACTALKINE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

EID: 70450267603     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000257494     Document Type: Article

References (30)

1. Balentine DA, Wiseman SA, Bouwens LC: The chemistry of tea flavonoids. Crit Rev Food Sci Nutr 1997;37:693-704.
2. Cabrera C, Artacho R, Gimenez R: Beneficial effects of green tea-a review. J Am Coll Nutr 2006;25:79-99.
3. Frei B, Higdon JV: Antioxidant activity of tea polyphenols in vivo: evidence from animal studies. J Nutr 2003;133:3275S-3284S.
4. Chyu K Y, Babbidge SM, Zhao X, Dandillaya R, Rietveld AG, Yano J, Dimayuga P, Cercek B, Shah PK: Differential effects of green tea-derived catechin on developing versus established atherosclerosis in apolipoprotein E-null mice. Circulation 2004;109:2448-2453. (Pubitemid 38679566)
5. Ludwig A, Lorenz M, Grimbo N, Steinle F, Meiners S, Bartsch C, Stangl K, Baumann G, Stangl V: The tea flavonoid epigallocatechin-3-gallate reduces cytokine-induced VCAM-1 expression and monocyte adhesion to endothelial cells. Biochem Biophys Res Commun 2004;316:659-665.
6. Hong MH, Kim MH, Chang HJ, Kim NH, Shin BA, Ahn BW, Jung YD: (-)-Epigallocatechin-3-gallate inhibits monocyte chemotactic protein-1 expression in endothelial cells via blocking NF-kappaB signaling. Life Sci 2007;80:1957-1965.
7. Umehara H, Bloom ET, Okazaki T, Nagano Y, Yoshie O, Imai T: Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler Thromb Vasc Biol 2004;24:34-40.
8. Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, Kakizaki M, Takagi S, Nomiyama H, Schall TJ, Yoshie O: Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997;91:521-530.
9. Fong AM, Robinson LA, Steeber DA, Tedder TF, Yoshie O, Imai T, Patel DD: Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 1998;188:1413-1419.
10. Pingiotti E, Cipriani P, Marrelli A, Liakouli V, Fratini S, Penco M, Giacomelli R: Surface expression of fractalkine receptor (CX3CR1) on CD4+/CD28 T cells in RA patients and correlation with atherosclerotic damage. Ann N Y Acad Sci 2007;1107:32-41.
11. Niess JH, Brand S, Gu X, Landsman L, Jung S, McCormick BA, Vyas JM, Boes M, Ploegh HL, Fox JG, Littman DR, Reinecker HC: CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science 2005;307:254-258.
12. Landsman L, Bar-On L, Zernecke A, Kim KW, Krauthgamer R, Shagdarsuren E, Lira SA, Weissman IL, Weber C, Jung S: CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood 2008.
13. Teupser D, Pavlides S, Tan M, Gutierrez-Ramos JC, Kolbeck R, Breslow JL: Major reduction of atherosclerosis in fractalkine (CX3CL1)-deficient mice is at the brachiocephalic artery, not the aortic root. Proc Natl Acad Sci U S A 2004;101:17795-17800.
14. Sung MJ, Kim W, Ahn SY, Cho CH, Koh G Y, Moon SO, Kim DH, Lee S, Kang KP, Jang K Y, Park SK: Protective effect of alpha-lipoic acid in lipopolysaccharide-induced endothelial fractalkine expression. Circ Res 2005;97:880-890.
15. Peng W, Chen J, Jiang Y, Wu J, Shou Z, He Q, Wang Y, Chen Y, Wang H: Urinary fractalkine is a marker of acute rejection. Kidney Int 2008;74:1454-1460.
16. Robinson LA, Nataraj C, Thomas DW, Howell DN, Griffiths R, Bautch V, Patel DD, Feng L, Coffman TM: A role for fractalkine and its receptor (CX3CR1) in cardiac allograft rejection. J Immunol 2000;165:6067-6072.
17. Foussat A, Bouchet-Delbos L, Berrebi D, Durand-Gasselin I, Coulomb-L'Hermine A, Krzysiek R, Galanaud P, Levy Y, Emilie D: Deregulation of the expression of the fractalkine/fractalkine receptor complex in HIV-1-infected patients. Blood 2001;98:1678-1686.
18. Ruth JH, Volin MV, Haines GK, 3rd, Woodruff DC, Katschke KJ, Jr., Woods JM, Park CC, Morel JC, Koch AE: Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis. Arthritis Rheum 2001;44:1568-1581.
19. Moon SO, Kim W, Sung MJ, Lee S, Kang KP, Kim DH, Lee SY, So JN, Park SK: Resveratrol suppresses tumor necrosis factor-alpha-induced fractalkine expression in endothelial cells. Mol Pharmacol 2006;70:112-119.
20. Abraham E, Singer M: Mechanisms of sepsis-induced organ dysfunction. Crit Care Med 2007;35:2408-2416.
21. Kim W, Moon SO, Lee S, Sung MJ, Kim SH, Park SK: Adrenomedullin reduces VEGF-induced endothelial adhesion molecules and adhesiveness through a phosphatidylinositol 3'-kinase pathway. Arterioscler Thromb Vasc Biol 2003;23:1377-1383.
22. Garcia GE, Xia Y, Chen S, Wang Y, Ye RD, Harrison JK, Bacon KB, Zerwes HG, Feng L: NF-kappaB-dependent fractalkine induction in rat aortic endothelial cells stimulated by IL-1beta, TNF-alpha, and LPS. J Leukoc Biol 2000;67:577-584.
23. Scaldaferri F, Sans M, Vetrano S, Correale C, Arena V, Pagano N, Rando G, Romeo F, Potenza AE, Repici A, Malesci A, Danese S: The role of MAPK in governing lymphocyte adhesion to and migration across the microvasculature in inflammatory bowel disease. Eur J Immunol 2009;39:290-300.
24. Jeong YJ, Choi YJ, Choi JS, Kwon HM, Kang SW, Bae JY, Lee SS, Kang JS, Han SJ, Kang YH: Attenuation of monocyte adhesion and oxidised LDL uptake in luteolin-treated human endothelial cells exposed to oxidised LDL. Br J Nutr 2007;97:447-457.
25. Lesnik P, Haskell CA, Charo IF: Decreased atherosclerosis in CX3CR1-/-mice reveals a role for fractalkine in atherogenesis. J Clin Invest 2003;111:333-340.
26. Patel A, Jagadesham VP, Porter KE, Scott DJ, Carding SR: Characterisation of fractalkine/CX3CL1 and fractalkine receptor (CX3CR1) expression in abdominal aortic aneurysm disease. Eur J Vasc Endovasc Surg 2008;36:20-27.
27. Nevo I, Sagi-Assif O, Meshel T, Ben-Baruch A, Johrer K, Greil R, Trejo LE, Kharenko O, Feinmesser M, Yron I, Witz IP: The involvement of the fractalkine receptor in the transmigration of neuroblastoma cells through bone-marrow endothelial cells. Cancer Lett 2009;273:127-139.
28. Yu YR, Fong AM, Combadiere C, Gao JL, Murphy PM, Patel DD: Defective antitumor responses in CX3CR1-deficient mice. Int J Cancer 2007;121:316-322.
29. Lavergne E, Combadiere B, Bonduelle O, Iga M, Gao JL, Maho M, Boissonnas A, Murphy PM, Debre P, Combadiere C: Fractalkine mediates natural killer-dependent antitumor responses in vivo. Cancer Res 2003;63:7468-7474.
30. Nagle D G, Ferreira D, Zhou YD: Epigallocatechin-3-gallate (EGCG): chemical and biomedical perspectives. Phytochemistry 2006;67:1849-1855.